Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J.
Zinzani PL, et al.
Blood Adv. 2022 Jan 25;6(2):590-599. doi: 10.1182/bloodadvances.2021004970.
Blood Adv. 2022.
PMID: 34644372
Free PMC article.
The EORTC QoL Questionnaire Core 30 (QLQ-C30) and EuroQoL EQ-5D were administered at baseline, every 6 weeks until week 24, and every 12 weeks thereafter. ...Compared with BV, pembrolizumab prolonged TTD for GHS/QoL (hazard ratio, 0.40 [95% CI, 0.22-0.74]; P = .003) …
The EORTC QoL Questionnaire Core 30 (QLQ-C30) and EuroQoL EQ-5D were administered at baseline, every 6 weeks until week 24, and every …